Another step towards providing a high-quality, safe and affordable treatment option for patients with severe chronic inflammatory diseases, together with our commercialization partner Fresenius Kabi: The FDA has accepted the #BLA for our Ustekinumab biosimilar candidate FYB202 for review.
Read more in our press release.
